Biotech · Private company · San Jose, CA, US
Cessation Therapeutics, Inc.
Track this companyFree. Adds Cessation Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials10 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- CSX-1004Phase 1 · Opioid OverdoseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Safety, Tolerability, and Pharmacokinetics of CSX-1004PHASE1 · COMPLETED · started Aug 1, 2023ClinicalTrials.gov NCT06005402 · fetched Nov 12, 2026
NIH awards2
- Development of the anti-fentanyl monoclonal antibody, CSX-1004, for prophylaxis against fentanyl and fentanyl analog overdoseFiscal year 2026 · $2.1MNIH RePORTER 5U01DA063352-02 · fetched Nov 12, 2026
- Development of the anti-fentanyl monoclonal antibody, CSX-1004, for prophylaxis against fentanyl and fentanyl analog overdoseFiscal year 2025 · $2.6MNIH RePORTER 1U01DA063352-01 · fetched Nov 12, 2026